Quote:

---

SRPT went from $35 a year ago to $150 today. There was a 40% jump the past couple of days on positive news on a phase 1/2a study.

---

Good advice on the Roth. I'd like to put a finer point on the SRTP news.

SRTP
N=3 interim phase 1/2a Muscular Dystrophy results. $3.7B market cap appreciation.
~$10B market cap

IPIX
B-UP N=15 phase 2 results. Knocked it out of the park good.
B-OM N=30 phase 2 results. Very good.
B-ABX N=~50 phase 2b. Very good single dose results.
K N=2 phase 2 results. Show p53 modulation in humans.
P N=80+ 300mg TBD
~$55M market cap

One cannot discount the appreciation IPIX will experience once they get some real cash in the bank, validation from a deal, and a listing on NASDAQ. Interim results on three patients boosted SRTP's market cap $3.7B! Why? Because they have cash, NASDAQ listing, and a have brought a drug to market. These interim results were really about as conclusive and compelling as the Kevetrin phase 2a.

If IPIX had $100M in the bank it would be a billion dollar company right now. The cash crunch will pass. Once it does we will be impervious to attack and will get proper recognition. We just have to shake the bad optics.